FLOW trial stopped early due to evidence of renal protection with semaglutide

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal. Cardiovascular pharmacotherapy 2024-01, Vol.10 (1), p.7-9
Hauptverfasser:	Gragnano, Felice, De Sio, Vincenzo, Calabrò, Paolo
Format:	Artikel
Sprache:	eng
Schlagworte:	Chronic kidney failure Glucagon-Like Peptides - adverse effects Humans Hypoglycemic Agents - adverse effects Kidney Pharmaceutical industry Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	9
container_issue	1
container_start_page	7
container_title	European heart journal. Cardiovascular pharmacotherapy
container_volume	10
creator	Gragnano, Felice De Sio, Vincenzo Calabrò, Paolo
description
doi_str_mv	10.1093/ehjcvp/pvad080
format	Article
fullrecord	<record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2887477081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A785088592</galeid><oup_id>10.1093/ehjcvp/pvad080</oup_id><sourcerecordid>A785088592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-ce7e0c2d9399b07861132196d0ce01e04613f2821a0d7eefaeca875af890bed13</originalsourceid><addsrcrecordid>eNqF0U1rGzEQBmARWprg-tpjEPTSHJyMVrsr6WhM8wEOvrT0KGRpNlHYXW0lrYP_fdfYzSkQ5qBBPDMMvIR8Y3DNQPEbfH6xu-Fm2BkHEs7IRQFVtahlWX1667k4J_OUXgCA1bIuJP9CzrlQvKxUdUEeb9ebPzRHb1qachgGdBRNbPfUjUhzoLjzDnuLNDQ0Yj-xIYaMNvvQ01efn2nCzjy1Y57cV_K5MW3C-emdkd-3P3-t7hfrzd3Darle2JLXeWFRINjCKa7UFoSsGeMFU7UDi8AQyprxppAFM-AEYmPQGikq00gFW3SMz8iP497plr8jpqw7nyy2rekxjEkXUopSCJAH-v1In0yL2vdNyNHYA9dLISuQslLFpK7fUVM57LwNPTZ--n9vwMaQUsRGD9F3Ju41A30IRx_D0adwpoHL08njtkP3xv9HMYGrIwjj8NGyfzk8maM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2887477081</pqid></control><display><type>article</type><title>FLOW trial stopped early due to evidence of renal protection with semaglutide</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Gragnano, Felice ; De Sio, Vincenzo ; Calabrò, Paolo</creator><creatorcontrib>Gragnano, Felice ; De Sio, Vincenzo ; Calabrò, Paolo</creatorcontrib><identifier>ISSN: 2055-6837</identifier><identifier>EISSN: 2055-6845</identifier><identifier>DOI: 10.1093/ehjcvp/pvad080</identifier><identifier>PMID: 37934595</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Chronic kidney failure ; Glucagon-Like Peptides - adverse effects ; Humans ; Hypoglycemic Agents - adverse effects ; Kidney ; Pharmaceutical industry ; Type 2 diabetes</subject><ispartof>European heart journal. Cardiovascular pharmacotherapy, 2024-01, Vol.10 (1), p.7-9</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. 2023</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-ce7e0c2d9399b07861132196d0ce01e04613f2821a0d7eefaeca875af890bed13</citedby><cites>FETCH-LOGICAL-c436t-ce7e0c2d9399b07861132196d0ce01e04613f2821a0d7eefaeca875af890bed13</cites><orcidid>0000-0002-6943-278X ; 0000-0002-5018-830X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37934595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gragnano, Felice</creatorcontrib><creatorcontrib>De Sio, Vincenzo</creatorcontrib><creatorcontrib>Calabrò, Paolo</creatorcontrib><title>FLOW trial stopped early due to evidence of renal protection with semaglutide</title><title>European heart journal. Cardiovascular pharmacotherapy</title><addtitle>Eur Heart J Cardiovasc Pharmacother</addtitle><subject>Chronic kidney failure</subject><subject>Glucagon-Like Peptides - adverse effects</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Kidney</subject><subject>Pharmaceutical industry</subject><subject>Type 2 diabetes</subject><issn>2055-6837</issn><issn>2055-6845</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1rGzEQBmARWprg-tpjEPTSHJyMVrsr6WhM8wEOvrT0KGRpNlHYXW0lrYP_fdfYzSkQ5qBBPDMMvIR8Y3DNQPEbfH6xu-Fm2BkHEs7IRQFVtahlWX1667k4J_OUXgCA1bIuJP9CzrlQvKxUdUEeb9ebPzRHb1qachgGdBRNbPfUjUhzoLjzDnuLNDQ0Yj-xIYaMNvvQ01efn2nCzjy1Y57cV_K5MW3C-emdkd-3P3-t7hfrzd3Darle2JLXeWFRINjCKa7UFoSsGeMFU7UDi8AQyprxppAFM-AEYmPQGikq00gFW3SMz8iP497plr8jpqw7nyy2rekxjEkXUopSCJAH-v1In0yL2vdNyNHYA9dLISuQslLFpK7fUVM57LwNPTZ--n9vwMaQUsRGD9F3Ju41A30IRx_D0adwpoHL08njtkP3xv9HMYGrIwjj8NGyfzk8maM</recordid><startdate>20240105</startdate><enddate>20240105</enddate><creator>Gragnano, Felice</creator><creator>De Sio, Vincenzo</creator><creator>Calabrò, Paolo</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6943-278X</orcidid><orcidid>https://orcid.org/0000-0002-5018-830X</orcidid></search><sort><creationdate>20240105</creationdate><title>FLOW trial stopped early due to evidence of renal protection with semaglutide</title><author>Gragnano, Felice ; De Sio, Vincenzo ; Calabrò, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-ce7e0c2d9399b07861132196d0ce01e04613f2821a0d7eefaeca875af890bed13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chronic kidney failure</topic><topic>Glucagon-Like Peptides - adverse effects</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Kidney</topic><topic>Pharmaceutical industry</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gragnano, Felice</creatorcontrib><creatorcontrib>De Sio, Vincenzo</creatorcontrib><creatorcontrib>Calabrò, Paolo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal. Cardiovascular pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gragnano, Felice</au><au>De Sio, Vincenzo</au><au>Calabrò, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FLOW trial stopped early due to evidence of renal protection with semaglutide</atitle><jtitle>European heart journal. Cardiovascular pharmacotherapy</jtitle><addtitle>Eur Heart J Cardiovasc Pharmacother</addtitle><date>2024-01-05</date><risdate>2024</risdate><volume>10</volume><issue>1</issue><spage>7</spage><epage>9</epage><pages>7-9</pages><issn>2055-6837</issn><eissn>2055-6845</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>37934595</pmid><doi>10.1093/ehjcvp/pvad080</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-6943-278X</orcidid><orcidid>https://orcid.org/0000-0002-5018-830X</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2055-6837
ispartof	European heart journal. Cardiovascular pharmacotherapy, 2024-01, Vol.10 (1), p.7-9
issn	2055-6837 2055-6845
language	eng
recordid	cdi_proquest_miscellaneous_2887477081
source	MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects	Chronic kidney failure Glucagon-Like Peptides - adverse effects Humans Hypoglycemic Agents - adverse effects Kidney Pharmaceutical industry Type 2 diabetes
title	FLOW trial stopped early due to evidence of renal protection with semaglutide
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A16%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FLOW%20trial%20stopped%20early%20due%20to%20evidence%20of%20renal%20protection%20with%20semaglutide&rft.jtitle=European%20heart%20journal.%20Cardiovascular%20pharmacotherapy&rft.au=Gragnano,%20Felice&rft.date=2024-01-05&rft.volume=10&rft.issue=1&rft.spage=7&rft.epage=9&rft.pages=7-9&rft.issn=2055-6837&rft.eissn=2055-6845&rft_id=info:doi/10.1093/ehjcvp/pvad080&rft_dat=%3Cgale_proqu%3EA785088592%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2887477081&rft_id=info:pmid/37934595&rft_galeid=A785088592&rft_oup_id=10.1093/ehjcvp/pvad080&rfr_iscdi=true